Monday, 20 December 2021 17:11

Colombia closes agreement for the co-development of vaccines with ARNm technology

Written by Evelyn Alas

One of the main opportunities left by the COVID-19 pandemic in Latin American countries is to strengthen the transfer of knowledge for scientific and technological development to face emerging infectious diseases.

Understanding this need, VaxThera and Minsalud, in alliance with the Canadian company Providence Therapeutics Holdings Inc, recognized worldwide for producing vaccines and therapies for infectious diseases and against cancer, are advancing an agreement that will turn Colombia into a biotechnology center for the Latin American market of vaccines and biologics.

"This agreement will address the country's needs in terms of prevention and timely treatment of infectious diseases, in addition to positioning the skills and scientific talent that Colombia has", says Jorge Emilio Osorio, president and founder of VaxThera.

This agreement seeks to train human talent and transfer ARNm technology for the production of vaccines, the same used by the pharmaceutical companies Pfizer and Moderna. Likewise, the production, finishing and distribution of a high quality vaccine to combat coronavirus and other diseases will continue.

"Signing this agreement in Colombia fills us with joy, as our goal as a company is to bring new RNAm vaccines to patients in need around the world and help fight COVID-19, as well as other diseases", commented Brad Sorenson, CEO of Providence Therapeutics.

By 2023, VaxThera will have its own biotech research center in the country, which will have the highest standards of innovation and care for the development of vaccines and biologics and where it expects to produce up to 100 million doses per year.